Loading...

Purified anti-human CD3 Antibody

Pricing & Availability
Clone
OKT3 (See other available formats)
Regulatory Status
RUO
Workshop
HCDM listed
Other Names
T3, CD3ε
Isotype
Mouse IgG2a, κ
Ave. Rating
Submit a Review
Product Citations
publications
OKT3_Purified_053107
Human peripheral blood lymphocytes stained with purified OKT3, followed by anti-mouse IgGs-FITC
  • OKT3_Purified_053107
    Human peripheral blood lymphocytes stained with purified OKT3, followed by anti-mouse IgGs-FITC
Cat # Size Price Quantity Check Availability Save
317301 25 µg 24€
Check Availability


Need larger quantities of this item?
Request Bulk Quote
317302 100 µg 44€
Check Availability


Need larger quantities of this item?
Request Bulk Quote
Description

CD3ε is a 20 kD chain of the CD3/T cell receptor (TCR) complex, which is composed of two CD3ε, one CD3γ, one CD3δ, one CD3ζ (CD247), and a T cell receptor (α/β or γ/δ) heterodimer. It is found on all mature T lymphocytes, NK T cells, and some thymocytes. CD3, also known as T3, is a member of the immunoglobulin superfamily that plays a role in antigen recognition, signal transduction, and T cell activation.

Product Details
Technical Data Sheet (pdf)

Product Details

Reactivity
Human
Antibody Type
Monoclonal
Host Species
Mouse
Formulation
Phosphate-buffered solution, pH 7.2, containing 0.09% sodium azide.
Preparation
The antibody was purified by affinity chromatography.
Concentration
0.5 mg/ml
Storage & Handling
The antibody solution should be stored undiluted between 2°C and 8°C, and protected from prolonged exposure to light. Do not freeze.
Application

FC - Quality tested
IHC-F - Reported in the literature, not verified in house
Recommended Usage

Each lot of this antibody is quality control tested by immunofluorescent staining with flow cytometric analysis. For flow cytometric staining, the suggested use of this reagent is ≤0.25 µg per million cells in 100 µl volume. It is recommended that the reagent be titrated for optimal performance for each application.

Application Notes

The OKT3 monoclonal antibody reacts with an epitope on the epsilon-subunit within the human CD3 complex.

Clone OKT3 can block the binding of clones SK7 and UCHT1.4 The OKT3 antibody is able to induce T cell activation. Additional reported applications (for the relevant formats) include: immunohistochemical staining of acetone-fixed frozen sections and activation of T cells. The LEAF™ purified antibody (Endotoxin <0.1 EU/µg, Azide-Free, 0.2 µm filtered) is recommended for functional assays (Cat. No. 317304). For highly sensitive assays, we recommend Ultra-LEAF™ purified antibody (Cat. No. 317326) with a lower endotoxin limit than standard LEAF™ purified antibodies (Endotoxin <0.01 EU/µg).

Application References
  1. Schlossman S, et al. Eds. 1995. Leucocyte Typing V. Oxford University Press. New York.
  2. Knapp W. 1989. Leucocyte Typing IV. Oxford University Press New York.
  3. Barclay N, et al. 1997. The Leucocyte Antigen Facts Book. Academic Press Inc. San Diego.
  4. Li B, et al. 2005. Immunology 116:487.
  5. Jeong HY, et al. 2008. J. Leuckocyte Biol. 83:755. PubMed
  6. Alter G, et al. 2008. J. Virol. 82:9668. PubMed
  7. Manevich-Mendelson E, et al. 2009. Blood 114:2344. PubMed
  8. Pinto JP, et al. 2010. Immunology. 130:217. PubMed
  9. Biggs MJ, et al. 2011. J. R. Soc. Interface. 8:1462. PubMed
Product Citations
  1. Winkler M, et al. 2017. PLoS One.. 10.1371/journal.pone.0182427. PubMed
  2. Qiu H, et al. 2017. Exp Cell Res.. 10.1016/j.yexcr.2017.08.036. PubMed
  3. Lang C, Wang J, and Chen L 2017. Exp Cell Res.. 10.1016/j.yexcr.2017.09.030. PubMed
  4. Thomi R, et al. 2017. Br J Dermatol.. 10.1111/bjd.15458. PubMed
  5. Jin Y, et al. 2017. Int Immunopharmacol. . 10.1016/j.intimp.2017.10.009. PubMed
  6. Pawlak EN, et al. 2018. Retrovirology. 15:6. PubMed
  7. Yarzabek B et al. 2018. eLife. 7 pii: e34961. PubMed
  8. Broos K, et al. 2019. Cancers (Basel). 11. PubMed
  9. Xiong Y, et al. 2019. J Immunol. 203:3023. PubMed
  10. Dutertre CA, et al. 2020. Immunity. 51(3):573-589.e8.. PubMed
  11. Alcántara‐Hernández M et al. 2017. Immunity. 47(6):1037-1050 . PubMed
  12. Nissim L et al. 2017. Cell. 171(5):1138-1150 . PubMed
  13. Schoknecht T, et al. 2017. J Leukoc Biol. 101:589. PubMed
  14. Crome SQ, et al. 2017. Nat Med. 1.213888889. PubMed
  15. Kessel C, et al. 2017. Arthritis Rheumatol. 69:1480. PubMed
  16. Singh AK, et al. 2017. Front Immunol. 0.513888889. PubMed
  17. García–Ortiz A, et al. 2017. PLoS Biol. 15:e2000653. PubMed
  18. Liu Z, et al. 2017. Oncotarget. 8:53518. PubMed
  19. Horn LA, et al. 2017. Oncotarget. 8:57964. PubMed
  20. Johnston HE, et al. 2018. Mol Cell Proteomics. 1.247222222. PubMed
  21. Bae EA, et al. 2018. Cancer Res. 78:5315. PubMed
  22. Meng Q, et al. 2018. Sci Rep. 8:17079. PubMed
  23. Mayer KE, et al. 2019. Theranostics. 4.548611111. PubMed
  24. Escudero–Pérez B, et al. 2019. JCI Insight. 4:e126070. PubMed
  25. Terzuoli E, et al. 2019. Cancers (Basel). 1.821527778. PubMed
  26. Sneddon S, et al. 2020. Oncoimmunology. 9:1684713. PubMed
  27. Seo N, et al. 2018. Nat Commun. 9:435. PubMed
  28. Liang J, et al. 2017. Nat Commun. 8:15732. PubMed
  29. Auladell M, et al. 2019. Clin Transl Immunology. 8:e01090. PubMed
  30. Ardain A, et al. 2019. Nature. 570:528. PubMed
  31. Boutboul D, et al. 2018. J Clin Invest. 128:3071. PubMed
  32. Bluhm J, et al. 2018. Mol Ther. 26:1906. PubMed
  33. Holbrook AK, et al. 2019. Physiol Rep. 7:e14234. PubMed
  34. Caielli S, et al. 2019. Nat Med. 25:75. PubMed
  35. Chevalier MF, et al. 2017. J Clin Invest. 127:2916. PubMed
  36. Benabdallah B, et al. 2019. Front Immunol. 10:2580. PubMed
  37. Hashimoto M, et al. 2017. Int J Inflam. 2017:1324735. PubMed
  38. Yin Y, et al. 2017. J Allergy Clin Immunol. 139:1701. PubMed
  39. Willing A, et al. 2018. J Immunol. 200:974. PubMed
  40. Tripathi T, et al. 2019. Immunohorizons. 0.201388889. PubMed
  41. Kujawski M, et al. 2019. BMC Cancer. 1.404166667. PubMed
  42. Ghosh S, et al. 2020. Cell Reports. 30(10):3434-3447. PubMed
  43. Walk J, et al. 2020. Front Immunol. 2.405555556. PubMed
  44. Zhao R, et al. 2018. Oncoimmunology. 8:e1509173. PubMed
  45. Mehta N, et al. 2020. Sci Rep. 10:15171. PubMed
  46. Leylek R, et al. 2020. Cell Rep. 32:108180. PubMed
  47. Bertino P, et al. 2019. Oncoimmunology. 8:1601482. PubMed
  48. Mousset CM, et al. 2018. Oncoimmunology. 7:e1488565. PubMed
  49. Siegers GM, et al. 2020. Front Immunol. 1.352083333. PubMed
  50. Alter G, et al. 2008. J Virol. 82:9668. PubMed
  51. Jeong H, et al. 2008. J Leukoc Biol. 83:755. PubMed
  52. Manevich-Mendelson E, et al. 2009. Blood. 114:2344. PubMed
  53. Biggs M, et al. 2011. J R Soc Interface. 1.348611111. PubMed
  54. Pinto J, et al. 2010. Immunology. 130:217. PubMed
  55. Blas-Rus N, et al. 2016. Nat Commun. 7: 11389. PubMed
  56. Barzilai S, et al. 2017. Cell Rep. 18(3):685-699. PubMed
  57. Welch JL, et al. 2020. FEBS Lett. 594:695. PubMed
  58. Zavidij O, et al. 2020. Nat Cancer. 0.384027778. PubMed
  59. Hsu CY, et al. 2020. Frontiers in Immunology. 11:574839. PubMed
  60. Hu X, et al. 2021. British Journal of Pharmacology. 178(6):1445-1458. PubMed
  61. He Y, et al. 2021. eLife. 10:00. PubMed
  62. Srivastava S, et al. 2020. Cancer Cell. 39(2):193-208.e10. PubMed
  63. Chevrier S, et al. 2021. Cell Reports Medicine. 2(1):100166. PubMed
  64. Kaufmann M, et al. 2021. Med. 2(3):296-312.e8. PubMed
  65. Herati RS, et al. 2021. Cell Reports Medicine. 2(5):100262. PubMed
  66. Henrick BM, et al. 2021. Cell. . PubMed
  67. Nathan A, et al. 2021. Cell. 184(17):4401-4413.e10. PubMed
  68. Park S, et al. 2020. Biosens Bioelectron. 112389:165. PubMed
  69. Mann ER, et al. 2020. Sci Immunol. :5. PubMed
  70. Akhand SS, et al. 2020. Cancer Immunol Res. 8:1542. PubMed
  71. Amiad-Pavlov D, et al. 2021. Sci Adv. 7: . PubMed
  72. Ito T, et al. 2021. Commun Biol. 4:694. PubMed
  73. Shalata W, et al. 2021. Cancers (Basel). 13: . PubMed
  74. Fronik P, et al. 2021. J Med Chem. 64:12132. PubMed
  75. Chiou SH, et al. 2021. Immunity. 54:586. PubMed
  76. Müller TR, et al. 2021. Cell Rep Med. 2:100374. PubMed
  77. Gurusamy M, et al. 2021. Nat Commun. 12:6798. PubMed
  78. Levin SD, et al. 2020. Front Immunol. 10:3086. PubMed
  79. Carriche GM, et al. 2021. J Allergy Clin Immunol. 147:335. PubMed
  80. Li H, et al. 2020. Front Immunol. 11:1777. PubMed
  81. Garcia de Moura R, et al. 2021. Front Immunol. 12:632667. PubMed
  82. Willimsky G, et al. 2021. Elife. 10:. PubMed
  83. Hirama T, et al. 2021. JCI Insight. 6:. PubMed
  84. Cassioli C, et al. 2021. Front Cell Dev Biol. 9:673446. PubMed
  85. Malenica I, et al. 2021. Nat Commun. 12:5209. PubMed
  86. Moosmann C, et al. 2022. STAR Protoc. 3:101031. PubMed
  87. Fu Z, et al. 2021. Acta Pharm Sin B. 11:3925. PubMed
  88. Wilson AS, et al. 2022. Nat Commun. 13:528. PubMed
  89. Guo J, et al. 2022. J Immunother Cancer. 10:. PubMed
  90. Naranbhai V, et al. 2022. Cell. . PubMed
  91. , et al. 2021. Eur J Immunol. 51:2708. PubMed
  92. Wiedeman AE, et al. 2020. J Clin Invest. 130:480. PubMed
  93. Zuñiga J, et al. 2020. Int J Infect Dis. 94:4. PubMed
  94. Yang J, et al. 2020. Nat Commun. 11:4402. PubMed
  95. Bacot SM, et al. 2020. Int J Mol Sci. 21:. PubMed
  96. Kim G, et al. 2021. J Infect Dis. 224:1861. PubMed
  97. Mammadli M, et al. 2021. Clin Transl Med. 11:e625. PubMed
  98. Berkson JD, et al. 2020. Immunohorizons. 4:14. PubMed
  99. Weinhage T, et al. 2020. J Immunol. 205:56. PubMed
  100. Jilg N, et al. 2020. J Infect Dis. 222:1837. PubMed
  101. Wang Q, et al. 2020. J Immunother Cancer. 8:. PubMed
  102. Li L, et al. 2020. J Transl Med. 18:363. PubMed
  103. Lee YS, et al. 2021. J Immunother Cancer. 9:. PubMed
  104. Pan Y, et al. 2021. Br J Pharmacol. 178:4907. PubMed
  105. Alcántara-Hernández M, et al. 2021. Nat Protoc. 16:4855. PubMed
  106. Li G, et al. 2021. Oncoimmunology. 10:1983306. PubMed
  107. Dilchert J, et al. 2022. Antibodies (Basel). 11:. PubMed
  108. Glud EN, et al. 2022. Br J Cancer. Online ahead of print. PubMed
  109. Rivera-Cruz CM, et al. 2022. Cytotherapy. Online ahead of print. PubMed
  110. Kim SJ, et al. 2020. J Biol Chem. 296:100108. PubMed
  111. Saito T, et al. 2022. ACS Chem Biol. 17:217. PubMed
  112. Deepak HB, et al. 2022. Indian J Pharmacol. 54:183. PubMed
  113. Kim HS, et al. 2023. Bioact Mater. 21:241. PubMed
  114. Onnis A, et al. 2023. J Exp Med. 220: . PubMed
  115. Mohamed H, et al. 2023. Biomedicines. 11: . PubMed
  116. Davé E, et al. 2023. MAbs. 15:2160229. PubMed
  117. Hawley KM, et al. 2022. Proc Natl Acad Sci U S A. 119:e2209044119. PubMed
  118. Sun X, et al. 2023. Cell Death Dis. 14:242. PubMed
  119. Meadows AM, et al. 2023. iScience. 26:106578. PubMed
  120. Eberhardt F, et al. 2023. Int J Mol Med. 52:. PubMed
RRID
AB_571926 (BioLegend Cat. No. 317301)
AB_571927 (BioLegend Cat. No. 317302)

Antigen Details

Structure
Ig superfamily, the subunits CD3γ, CD3δ, CD3ζ (CD247) and TCR (α/β or γ/δ) form the CD3/TCR complex, 20 kD
Distribution

Mature T and NK T cells, thymocyte differentiation

Function
Antigen recognition, signal transduction, T cell activation
Ligand/Receptor
Peptide antigen bound to MHC
Cell Type
NKT cells, T cells, Thymocytes, Tregs
Biology Area
Immunology
Molecular Family
CD Molecules
Antigen References
  1. Barclay N, et al. 1993. The Leucocyte FactsBook. Academic Press. San Diego.
  2. Beverly P, et al. 1981. Eur. J. Immunol. 11:329.
  3. Lanier L, et al. 1986. J. Immunol. 137:2501.
Gene ID
916 View all products for this Gene ID
UniProt
View information about CD3 on UniProt.org
Go To Top Version: 2    Revision Date: 06-12-2013

8999 BioLegend Way, San Diego, CA 92121 www.biolegend.com
Toll-Free Phone: 1-877-Bio-Legend (246-5343) Phone: (858) 768-5800 Fax: (877) 455-9587

This data display is provided for general comparisons between formats.
Your actual data may vary due to variations in samples, target cells, instruments and their settings, staining conditions, and other factors.
If you need assistance with selecting the best format contact our expert technical support team.

ProductsHere
Login / Register
Remember me
Forgot your password? Reset password?
Create an Account